- Journalists Shed Light on Deadly Hantavirus Outbreak and a Crisis in the Nation’s ERs
- Is the horizon still bright for orthodontists?
- The Make America Healthy Again Movement Comes for Hospital Food
- What’s driving physicians to early retirement
- Why Tenet’s CEO says ASCs keep choosing USPI
- 12 recent hospital, health system president exits
- Hospitals embrace rapid opioid treatment in fentanyl era: Study
- Texas systems open 200-bed behavioral health center
- 32 health systems spending $5B on cancer care
- Sanford, North Memorial planned combination adds to Minnesota healthcare deal wave
- Lone Peak Dental Group acquires Arizona practice
- Inside Northwestern Medicine’s battle against surgeon burnout
- UT Austin launches Epic ahead of new academic medical center
- Ohio system names COO
- Buy, sell or fight: The new calculus of health system growth
- OpenAI’s growing healthcare footprint
- Tennessee optometrist pleads guilty to $6.9M Medicare fraud
- Why Cook County Health’s Medicaid coverage loss strategy is drawing attention
- Akron Children’s chosen for former Ohio college campus site
- Surgery Partners doubles down on orthopedics, robotics as total joint growth hits 14.6%
- The growing war over Anthem’s out-of-network penalty policy
- 3 PDS Health headlines to know in 1 week
- Remarks at the Conference on Financial Market Regulation
- Could ASCs help cardiology move past its ‘breaking point’?
- 3 programs expanding the anesthesia workforce in 2026
- Dad Jokes: Remarks at the 13th Annual Conference on Financial Markets Regulation
- UVM Health targets $300M in cuts, outpatient overhaul amid $280M deficit
- Maine behavioral health provider cites industry pressures in merger
- Dentists opening practices in 1 month
- The Aspen Group names new chief commercial officer
- RFK Jr. Launches Plan To Curb Antidepressant 'Overprescription'
- Georgia mental health provider adds after-hours outpatient program
- AI-augmented behavioral health provider Theris launches out of stealth
- 5 data breaches, settlements impacting cardiology
- Maine hospital adds stroke prevention, cardiac imaging services
- As new tech, AI sweeps the marketing world, Eversana Intouch’s new CEO is ‘comfortable in the gray’
- Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M
- Trump plans to fire FDA chief Marty Makary: report
- Trump plans to fire FDA chief Marty Makary: report
- Oregon governor signs behavioral health workforce expansion bills amid shortage
- Remarks at the Special Competitive Studies Project AI+ Expo
- Lawmakers, former FDA leaders and more rally behind mifepristone as Supreme Court weighs telemedicine access to abortion pill
- 5 DSOs making headlines
- Plant-Based Foods May Help Lower Risk of High Blood Pressure
- The ACA exchanges dominated Q1 earnings calls. Here's what payer, health system execs had to say
- Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
- Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'
- Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma
- Op-ed: It's time to make more strategic bets on AI in healthcare
- Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
- Super Shoes Might Increase Risk Of Running Injuries, Study Says
- TV, Movies Offer Flawed Depictions Of Autism, Add To Delayed Diagnosis, Study Says
- Opioid OD Survivors Have Triple Rate Of Repeat Overdoses Than Previously Estimated
- Revisiting Pharma’s tariff reality
- A New Medicare Option For Weight Loss Drugs: What Older Americans Should Know
- Exposure Therapy Can Successfully Ease Peanut Allergies
- Listen: A Federal Agency Is After Workers’ Health Data, and Critics Are Alarmed
- In California Governor Race, Single-Payer Is a Litmus Test. There’s Still No Way To Pay for It.
- AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard
- Johnson & Johnson launches ‘Generation Fine’ depression project
- Pre-launch efforts linked to lasting drug awareness edge: report
- GSK tees up a Modern Family for meningitis messaging
- NYC invests $12M in overdose recovery workforce
- Aspen Dental to pay $2M to settle allegations of violating corporate dentistry laws
- Texas dental practice relocates into 6K-square-foot facility
- Medit launches global orthodontics division, acquires California training institute
- Pennsylvania enacts dental faculty bill
- Cruise Ship Hantavirus Outbreak Kills 3 as WHO Says Risk Is Low
- How policy, reimbursement incentives, could help healthcare address its climate footprint
- Remarks at the 13th Annual Conference on Financial Market Regulation
- 5 best practices for financially integrating behavioral health
- Fierce Pharma Asia—Summit’s surprise interim trial miss; UCB’s $2B Candid buy; J&J’s CAR-T cuts
- Amazon Pharmacy to offer home delivery for Novo Nordisk's Ozempic pill
- New York expands behavioral health data access in EHRs
- Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
- New Hampshire to receive $29.5M in Purdue opioid settlement
- Behavioral health leaders counter HHS ‘overprescribing’ narrative
- Clover Health's MA membership grows 51% year-over-year
- New Study Suggests The Brain Can Continue Learning While In An Unconscious State
- Health Tech Weekly Rundown: Tether rolls out medical AI for phones, wearables; Medaptus launches operational ‘command center’
- Pennsylvania sues Character.ai over AI chatbot allegedly presenting itself as licensed medical professional
- Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
- FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
- Every 1,000 Steps After Surgery Cuts Complication Risk, Study Finds
- Bullying and Politics Fuel Suicide Risk for LGBTQ+ Teens and Young Adults, Survey Finds
- Head Impacts May Disrupt Gut Health Even Without Concussion
- Class of Migraine Drug, CGRP Inhibitors, Has Added Benefit: Reduced Glaucoma Risk
- States Eye Aid to Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- That Discount at the Pharmacy Counter May Pack Hidden Costs
- Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
- Hims & Hers debuts its first AI care agent to interpret biomarker lab results
- Alnylam rebuked by FDA over efficacy claims on Amvuttra website
- Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive
- Oscar Health's profit hits $679M, membership rises in Q1
- Joint Commission, NACHC partner on training, new accreditation for community health centers
- Ardent Health touts outpatient growth, checked labor spend during hectic Q1
- FDA Authorizes Fruit-Flavored Vapes for Adults
- Sanofi asks to pull Tzield bid from FDA's controversial CNPV program: report
- FDA rolls out 1-day assessment pilot in bid to refocus inspection resources
- Nearly 8 in 10 employers say GLP-1 coverage drives up benefit costs: Business Group on Health
- Edibles + Alcohol Combo Poses Driving Risks Missed by Sobriety Tests
- Leapfrog Group's latest safety grades have far fewer low scores since removal of non-participating hospitals
- VR Training Helps Autistic People Navigate Police Encounters
- Novo CEO cites pricing 'sweet spot' as Wegovy pill debuts with $355M quarter
- Weight Loss Surgeries Fall More Than 20% As Patients Turn To GLP-1 Meds, Experts Say
- FDA blocks publication of COVID, shingles vaccine safety studies: NYT
- Bayer diagnoses how to build trust in cell and gene therapies
- Amwell boasts higher than expected renewals, retention despite Q1 revenue decline
- First Psych Ward Stay Signals Long-Term Mental Health Struggles For Nearly All Patients
- Why Melatonin Shouldn't Be A Bedtime Go-To For Kids
- Children Living Near Gas Stations Have Higher Cancer Risk, Study Finds
- The timing is right for psychedelics manufacturer Optimi Health's IPO
- HHS' Healthy Food Agenda Puts Hospitals On Notice About Patients' Meals
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
- Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support
- Inside the gaps in fertility and surrogacy systems
- CVS execs say company on track to meet MA margin goals by 2028
- Facilitating Access to Trump Accounts
- Fixing Failures to Communicate
- Hinge Health lifts 2026 outlook after strong Q1 as it expands to new conditions
- For nonprofit hospitals, pricey management consultants haven't yielded better performances: study
- Supreme Court Issues Stay, Keeping Abortion Pill Mifepristone Available by Mail For Now
- Statement on Proposing Release for Semiannual Reporting
- Quarterly Questions: Statement on the Proposed Amendments to Allow Semiannual Reporting
- Statement on Proposing Semiannual Reporting
- Wellstar partners with BD to implement AI-driven medication management system
- Listen to the Latest ‘KFF Health News Minute’
- Newer Migraine Drugs Reduce Headache Days With Fewer Side Effects
- New Drug Combo Effective Against Treatment-Resistant IBD, Trials Show
- New Warning Labels Might Help People Cut Back On Drinking
- Ozempic Can Curb Cravings in Alcohol Use Disorder, Landmark Trial Finds
- US on the Brink of Losing Measles-free Status, Study Warns
- Delays in Visa Program Threaten Doctor Placements in Underserved Areas
- States Eye Aid To Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- Supreme Court Puts Brakes on Abortion Pill Restrictions
- FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib
- Online Misinformation Adding To Americans' Skin Cancer Risk, Survey Finds
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Social Media Videos, Easy Access Raise Risk of Teen Inhalant Use
- Staff Statement Regarding Pooled Employer Plans
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- 'Fitspirational' Posts Can Be More Harmful Than Motivational, Review Concludes
- Parents’ Stress Tied to Children’s Mental Health, New Survey Finds
- Surgeon Multitasking Increases Death Risk Of Organ Transplantees
- When Natural Disasters Strike, Another Crisis Hits Those Recovering From Opioid Addiction
- FDA Recalls Several Ghirardelli Powdered Beverages Over Potential Contamination
People across the country are reporting illnesses after microdosing psilocybin with mushroom products from Diamond Shruumz of California. Microdosing involves taking very small doses of psychedelics in specially selected mushroom varieties, typically 10% to 20% of recreational doses.
The Michigan Department of Health and Human Services is warning Michigan's trend setters not to eat Diamond-Shruumz products. The U.S. FDA and Centers for Disease Control and Prevention are investigating illnesses associated with Diamond Shruumz-brand microdosing chocolate bars, infused cones, or microdose and macrodose gummies. The products are labeled as having a blend of mushroom varieties like Reishi and Lion's Mane. Their active ingredient, psilocybin is classified as a hallucinogen. Psilocybin used to cause all kinds of strange behaviors 50 years ago when it was a popular street drug.
Psilocybin mushrooms have been decriminalized in Ann Arbor and Detroit.
MDHHS alerting Michigan residents not to eat Diamond Shruumz-brand chocolate bars, cones and gummies during ongoing FDA investigation
By Lynn Sutfin - June 18, 2024LANSING, Mich.-The Michigan Department of Health and Human Services (MDHHS) and the Food and Drug Administration (FDA) are urging Michigan residents not to eat, sell or serve any flavor of Diamond Shruumz-brand Microdosing Chocolate Bars, Infused Cones or Micro Dose and Macro Dose gummies, and instead throw them away. The products are labeled as containing a proprietary blend of mushrooms such as reishi and lion’s mane.
“People in multiple states have become ill after eating these products, reporting a variety of severe symptoms,” said Dr. Natasha Bagdasarian, chief medical executive. “As these products look similar to candy, we urge parents and caregivers to consider discussing this information with their teens even though they are intended for individuals 18 and older. We are advising that everyone avoid these products.”
As of Friday, June 7, the FDA and Centers for Disease Control and Prevention (CDC), in collaboration with America’s Poison Centers and state and local partners, are investigating a series of illnesses associated with eating Diamond Shruumz-brand products. The FDA is working to determine the cause of these illnesses.
A total of 26 illnesses have been reported from 16 states, including Alabama, Arizona, California, Indiana, Kentucky, Maryland, Minnesota, Missouri, Montana, Nevada, New Jersey, New York, North Carolina, Pennsylvania, South Carolina and Tennessee. To date, there are no reported cases in Michigan.
Of those who became ill, 25 people reported seeking medical care, with 16 being hospitalized. No deaths have been reported. People who became ill from eating Diamond Shruumz-brand products reported a variety of severe symptoms including seizures, central nervous system depression (loss of consciousness, confusion, sleepiness), agitation, abnormal heart rates, hyper/hypotension, nausea and vomiting.
Diamond Shruumz-brand products can be purchased online or at a variety of retail locations nationwide, including smoke/vape shops or places that sell hemp-derived or CBD products.
Retailers should not sell or distribute any of these products. Instead, hold these products until further direction is given by the FDA.
Those who become ill after consuming these products should seek medical treatment. They can also call the Poison Help Line at 800-222-1222 to report symptoms and seek information. Callers should let Poison Control know they have recently consumed a Diamond Shruumz-brand chocolate bars, cone or gummies.
Health care providers should report these illnesses to their local health department or the Poison Help Line at 800-222-1222.
MDHHS will continue to monitor incoming information from FDA. Consumers and health care providers can monitor updates about this investigation at Investigation of Illnesses: Diamond Shruumz-Brand Chocolate Bars, Cones, & Gummies (June 2024) | FDA.
Physicians or residents with questions or concerns can contact MDHHS by calling 844-464-7327 or emailing mdhhs-eht@michigan.gov.
FDA is now investigating one death associated with these Diamond Shruumz microdose products, and it is now believed that the toxic agent which caused these sicknesses is muscimol not psilocybin:
https://www.upi.com/Health_News/2024/07/03/Diamond-Shruumz-death/5371719992921/
FDA probing death potentially linked to recalled microdosing candies
By Darryl Coote - July 3, 2024July 3 (UPI) -- Federal food safety officials are investigating a potential death linked to ingesting recalled microdosing chocolates and candies that have sickened dozens of people across the United States.
All Diamond Shruumz-brand chocolates and gummies were recalled late last month over the products containing toxic levels of muscimol, a chemical found in some mushrooms that can cause seizures, involuntary muscle contractions and a loss of consciousness, among other issues.
At least 48 illnesses linked to the edibles have been reported in 24 states as of Monday, the Food and Drug Administration said in an update to the recall on Tuesday.
Twenty-seven of the patients have been hospitalized, it said, adding that there is one potentially associated death under investigation.
American Poison Centers in a statement added that it has received 82 reports of exposure associated with the Diamond Shruumz products, including 48 cases of severe illness, of which all but two sought medical attention.
The FDA said those who became ill after eating Diamond Shruumz-brand products reported a variety of severe symptoms, including seizures, central nervous system depression, agitation, abnormal heart rates, nausea and vomiting.
Diamond Shruumz is instructing its customers to not eat their products amid the investigation. It said in a statment on its website that those who became ill from eating their products had consumed "the entire chocolate bar and some products containing higher levels of muscimol than normal."
The FDA is also recommending not to eat, sell or serve any flavor of Diamond Shruumz-brand chocolate bars, cones or gummies. Those in possession of the recalled products are being instructed to either discard them or return them to the company for a refund.
The products affected by the recall were sold online as well as at retail stores that sell such products, including smoke and vape shops.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.













